CHROMADEX CORPORATION (NASDAQ:CDXC) Files An 8-K Results of Operations and Financial Condition
Item 2.02.
|
Results of Operations and Financial Condition.
|
press release announcing its earnings for the quarter ended April
1, 2017. A copy of the press release is attached hereto as
Exhibit 99.1.
being furnished and shall not be deemed to be filed for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended
(the Exchange Act), or otherwise subject to the liability of that
section, nor shall they be deemed incorporated by reference in
any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference
in such filing.
|
Exhibit Number
|
Description
|
|
|
99.1
|
Press Release dated May 11, 2017.
|
|
About CHROMADEX CORPORATION (NASDAQ:CDXC)
Chromadex Corporation and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. The Company operates through three segments: Ingredients, which develops, supplies and commercializes ingredient technologies; Core standards and contract services, which supplies phytochemical reference standards, which are small quantities of plant-based compounds used to research an array of attributes, reference materials and related contract services, and Scientific and regulatory consulting, which provides scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage health and regulatory risks. CHROMADEX CORPORATION (NASDAQ:CDXC) Recent Trading Information
CHROMADEX CORPORATION (NASDAQ:CDXC) closed its last trading session down -0.20 at 3.46 with 319,721 shares trading hands.
